Lifemel Honey to Reduce Leucopenia During Chemotherapy

Rambam Health Care Campus60 enrolled

Overview

This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Breast Cancer

Interventions

Lifemel honey intake every dayBEHAVIORAL

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * breast cancer patient treated with adjuvant chemotherapy * PS = 2 or less Exclusion Criteria: * none

Outcomes

Primary Outcomes

Prevention of myelotoxicity-every week during chemotherapy.

Central Contacts

Georgeta Fried, MD

CONTACT

972-4-8543018 g_fried@rambam.health.gov.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.